Oric Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Oric Pharmaceuticals, Inc.
9.38
+27.08%
vs ±44.4% implied · ×0.61
shaded = implied · ▲▼ = realized
Oric Pharmaceuticals has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
SentenceIn January 2025, we announced that we entered into a clinical trial and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with SC amivantamab for the first line treatment of patients with advanced NSCLC with EGFR exon 20 mutations, and we initiated a Phase 1b trial in the first quarter of 2025.
SentenceWe also announced that we entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer, to evaluate rinzimetostat in combination with Erleada ® (apalutamide), Johnson & Johnson's AR inhibitor, and Nubeqa ® (darolutamide), Bayer's AR inhibitor.
ORIC 10-Kaccession 0001193125-26-064005
SentenceRinzimetostat (formerly ORIC-944), an allosteric inhibitor of the PRC2 via the EED subunit, for which we licensed development and commercialization rights from Mirati with the Mirati License Agreement.
ORIC 10-Kaccession 0001193125-26-064005
SentenceUnder the Mirati License Agreement, Mirati granted us a worldwide, exclusive, sublicensable, royalty-free license under Mirati's rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound.
ORIC 10-Kaccession 0001193125-26-064005
SentenceEnozertinib (formerly ORIC-114), a brain-penetrant, orally bioavailable, irreversible inhibitor targeting EGFR exon 20 and EGFR atypical mutations, for which we licensed development and commercialization rights from Voronoi with the Voronoi License Agreement.
ORIC 10-Kaccession 0001193125-26-064005
—
Expected move
No implied move.